Bruno Julianne
Known title: Chief Operating OfficerCIK: 0002019645
Associated companies
Synthesized from recent news and fundamentals/technical data -- not human analyst commentary or trader sentiment.
October 9, 2026
CRISPR Therapeutics to Share New Data at AHA and ACR 2026. CRISPR Therapeutics announced it will present late-breaking data at the American Heart Association and American College of Rheumatology conferences in 2026. These upcoming presentations are key events for the company, as they will provide new clinical insights into its treatments for heart and autoimmune conditions. The stock is currently trading near its 52-week low, making these data releases a significant factor for investors watching the company's progress.
Transaction History
| DMRA | ▲ Buy | Option Exercise | 129,000 | $0 | 2/9/2026 | View on chart |
| CRSP | ▼ Sell | Open Market | 1,714 | $71K | 3/21/2025 | View on chart |
| CRSP | ▲ Buy | Option Exercise | 3,750 | — | 3/20/2025 | View on chart |
| CRSP | ▼ Sell | Open Market | 190 | $8K | 3/12/2025 | View on chart |
| CRSP | ▼ Sell | Open Market | 1,198 | $51K | 3/11/2025 | View on chart |
| CRSP | ▲ Buy | Option Exercise | 435 | — | 3/11/2025 | View on chart |
| CRSP | ▲ Buy | Option Exercise | 2,399 | — | 3/10/2025 | View on chart |
| CRSP | ▼ Sell | Open Market | 333 | $18K | 2/19/2025 | View on chart |
| CRSP | ▲ Buy | Option Exercise | 650 | — | 2/18/2025 | View on chart |
| CRSP | ▼ Sell | Open Market | 3,366 | $189K | 6/21/2024 | View on chart |
| CRSP | ▲ Buy | Option Exercise | 7,000 | — | 6/20/2024 | View on chart |
AI Market Commentary
AI-generatedAll commentary →Synthesized from recent news and fundamentals/technical data -- not human analyst commentary or trader sentiment.
October 13, 2026
DMRA Shares Rise Amid Valuation Debate
Damora Therapeutics shares have climbed recently, drawing attention to potential overvaluation relative to book value. While the stock is trading near its 52-week low, analyst targets remain significantly higher than the current price. This divergence highlights a split between short-term technical weakness and long-term fundamental expectations.
DMRA Shares Rise Amid Valuation Debate. Damora Therapeutics shares have climbed recently, drawing attention to potential overvaluation relative to book value. While the stock is trading near its 52-week low, analyst targets remain significantly higher than the current price. This divergence highlights a split between short-term technical weakness and long-term fundamental expectations.